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ABSTRACT 
 
 
The initiation of highly active antiretroviral therapy has shown to result in successful 
suppression of viral replications followed by an increase in CD4 lymphocytes, a partial 
recovery of T-cell specific immune responses and decrease susceptibility to opportunistic 
pathogens. Aim: The aim of the present study was to determine the prevalence of oral 
lesions in patients before and after undergoing HAART. Methods: The study design was 
longitudinal and descriptive, investigating the prevalence of oral lesions presenting in 
HIV/AIDS patients at baseline, 3 and 6 months after taking HAART. A convenience 
sample size of 200 participants was targeted. Results: 210 HIV positive patients 
participated at baseline. At 3 months, 96 (46%) and at 6 months, 52 (25%) were available 
for review respectively. At baseline 210 HIV positive patients were recruited into the 
study from three hospitals.  Two infectious disease hospitals belonged to the City of 
Harare and the other is a government hospital. Just over two thirds were female (64.3%) 
and the age ranged as follows: 21-30 (17%); 31-40 (44%); 41-50 (26% and 51-60 (9%). 
Discussion: HAART appears to be effective in reducing the prevalence of oral lesions in 
persons with AIDS likely due to the immunological reconstitution. Oral candidiasis 
remains the most prevalent oral opportunistic infection in immuno-suppressed individuals 
and hence its important predictive value for immuno-suppression defined as CD4-cell 
count level <200/mL of blood. All oral lesions strongly associated with HIV infection 
with the exception of non-Hodgkin’s lymphoma were diagnosed at baseline. CD4 cell 
count level increased after initiation of HAART. T-lymphocytes that are formed after the 
introduction of HAART may not provide sufficient protection against some lesions like 
parotid gland disease and HPV conditions (planar warts). HAART failure was detected in 
some patients who had negative CD4-cell count at 6 months compared to the baseline 
parameters. Conclusions: HIV-positive patients experience oral pain during the course of 
their disease, eating, drinking and swallowing. Further longitudinal studies are required in 
order to ascertain the prevalence of these lesions at three and six months and the effect of 
HAART.  
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CHAPTER ONE: INTRODUCTION 
 
Oral manifestations of HIV infection include fungal, viral and bacterial infections. 
Neoplasms, periodontal disease, salivary gland disease and lesions of uncertain origin are 
also seen. Oral lesions such as candidiasis, herpetic ulcers and Kaposi’s sarcoma are 
among the first symptoms of HIV infection. These conditions cause pain, discomfort, 
eating restrictions, and provide a source of constant opportunistic infections. Early 
detection of HIV-related oral lesions can be used to diagnose HIV infection, elucidate 
progression of the disease, predict immune status, efficacy of HAART and can result in 
timely therapeutic intervention.  
 
The treatment and management of oral HIV lesions can considerably improve well-being 
(Naidoo and Chikte, 2004). Recent publications report that HAART reduces the 
prevalence of oral lesions in infected adults and children (Schmidt-Westhausen et al, 
2000; Ceballos-Salobrena et al, 2005; Miziara et al, 2005). These studies emanate mainly 
from North America and Europe; there are only 2 documented studies from the African 
continent, Nigeria and Tanzania (Olaniyi and Sunday, 2003; Hamza et al, 2006). 
 
Studies from Zimbabwe have documented the prevalence of oral manifestations in people 
with HIV/AIDS before the advent of HAART (Jonnson et al, 1998; Chidzonga, 2003). 
The programmeme of rolling out HAART, together with laboratory testing (CD4 cell 
count) began in April 2004 in Zimbabwe and 2006 in the City of Harare hospitals 
(MOHCW, April 2006). This provides an ideal opportunity to investigate the effect of 
HAART on oral lesions in an African population at baseline, 3 and 6 months. 
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CHAPTER TWO: LITERATURE REVIEW 
 
This chapter provides a review of the literature that is directly or indirectly related to this 
topic of study. 
2.1  Introduction 
 
The HIV/AIDS epidemic has caused untold suffering to millions of individuals and 
families in the world. 33.2 million people are estimated to be infected with the virus that 
causes AIDS globally. 22.5 million of the affected reside in sub-Saharan Africa, the 
epicentre.  Naturally, it has become the leading cause of death in the region. Women 
(61%) are more affected than men (UNAIDS, 2007). The life expectancy at birth in 9 
African countries has dropped below 40 years of age, including Zimbabwe (UNAIDS, 
2004). Zimbabwe with a population of about 12 million, is experiencing a mortality rate 
of 3 000 deaths per week from HIV-related illnesses (Looman and Barnabas, 2006). 
Estimates of 1.6 million people are living with HIV/AIDS are on record. A drop in 
prevalence from 24.6% to 20.1% and to18.1% in 2003, 2005 and 2006 respectively was 
reported (MOHCW, April 2006). In 2007, the prevalence dropped further to 15.6%. A 
total of 1 320 739 people are infected in Zimbabwe with 75 420 receiving ART and 404 
376 needing ART (MOHCW, 2007). 
 
Oral manifestations in HIV-infected patients have a prevalence of about 70-90% (Vaseliu 
et al, 2006). At least 40 types of oral lesions (OLs) have been identified (Miziara et al, 
2006). Oral lesions earn recognition as clinical indicators and earliest signs of HIV-
infection. They are predictors of disease progression and also used as clinical markers for 
the classification and staging of the disease (Vaseliu et al, 2006). Besides, they are 
indicators of treatment failure (Miziara and Weber, 2006). OLs are associated with oral 
discomfort and pain, which may interfere with speech, nutritional intake leading to 
malnutrition especially in children. The quality of life is affected (Naidoo, 2001). 
 
 
 
 
 
                                                                    10 
Oral lesions in HIV/AIDS patients before and after HAART treatment.  
 
The introduction of highly active anti retroviral therapy (HAART) in 1996 has 
significantly reduced the incidence rate of opportunistic infections (OIs) associated with 
HIV/AIDS including oral lesions (Nicolatou-Galitis et al, 2004; Hamza et al, 2006). 
Zimbabwe in April 2004 introduced HAART; in line with the WHO 3*5 Strategy 
(MOHCW, April 2006). The advent of HAART and improvement in laboratory tests 
necessitates the need to re- examine orofacial lesions in Zimbabwe. Studies before the era 
of HAART exist (Jonnson et al, 1998; Chidzonga, 2003). To date there are no published 
studies with relevance to the use of HAART and effects on oral lesions. This has become 
the basis of this research. 
 
2.2 HAART 
 
The initiation of highly active antiretroviral therapy has shown to result in successful 
suppression of viral replications followed by an increase in CD4 lymphocytes, a partial 
recovery of T-cell specific immune responses and decrease susceptibility to opportunistic 
pathogens.  
 
To date there are 4 classes of HAART drugs in use, administered in combinations to curb 
resistance development: 1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-
Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs) and 
Experimental Drugs (EDs).  EDs include: - a) Entry (Co-receptors) Inhibitors b) Fusion 
Inhibitors c) Integrase Inhibitors d) Maturation inhibitors (Frezzini et al, 2005). HAART 
is a combination of 2 or more NRTIs with at least 1PI and/ or 1NNRTIs.  
 
In Zimbabwe, the regimens are available in fixed dose combinations and referred to as 
triple therapy, in this document also referred to as generic HAART. First line regimen 
include zidovudine, stavudine, lamivudine, nevirapine, effavirenz). Second line regimen, 
with PIs are distinguished and are as follows abacavir, kaletra (lopinavir/ritonavir), 
saquinavir/ritonavir, didanosine (MOHCW/WHO, 2006). HAART is mainly used in 
public institutions for post exposure prophylaxis (PEP). 
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2.3 Advantages of using HAART 
 
HAART reduces the replication of virus thereby allowing the body's immune system to 
recover from the progressive destruction of CD4- cells. This in turn reduces HIV- related 
morbidity and eventually mortality (Umadevi et al, 2007). The quality of life is improved 
(Naidoo and Chikte, 2004; Hodgson, 2006). HAART transforms HIV/AIDS into a 
chronic manageable disease. The reduction of oral lesions minimizes the use of available 
resources in treating them. More people are accepting HIV testing and counselling. The 
stigma associated with the infection is also minimized since people know that treatment 
is available. The number of potential orphans is also reduced. HIV transmission is 
minimized and this forms the basis for PMTCT programmes. HIV/AIDS destroys and 
kills expensive and highly trained human resources at the very prime of their productive 
lives; HAART boosts economies and revitalizes communities (MOHCW, November 
2006). 
 
2.4 Oral side effects of HAART 
 
Adverse effects include oral warts, salivary gland disease (SGD) with or without 
xerostomia, taste alterations and mucosal hyperpigmentation. Furthermore drug specific 
effects have been noted in association with such lesions as recurrent oral ulcerations, 
erythema multiforme, toxic epidermal necrosis, lichenoid reactions, dysgeusia, cheilitis, 
and circumoral paresthesia. There is increased risk of developing squamous cell 
carcinoma (Hamza et al, 2006; Hodgson et al, 2006). Some syndromes emerging are 
lipodystrophy and Stevens-Johnson’s syndromes. Hyperglycaemia has been associated 
with the use of Protease Inhibitors (Aquino-Garcia et al, 2008). Apart from interfering 
with food intake, swallowing and speech, there is disfigurement as in the case after a 
herpes zoster attack (Greenspan, 2001; Frezzini et al, 2005, Hamza et al, 2006; Hodgson 
et al, 2006). 
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2.5 HAART and immunological parameters (CD4 count / Viral load) 
 
2.5.1 CD4 cell count 
 
CD4 cells are T-lymphocytes responsible for cell-mediated response combating 
infections in the body and activating humoral reactions by B-lymphocytes to produce 
immunoglobulins. Normal range is between 500 to 1500cells/ml of blood (Scully, 2004). 
The CD4 cells are targeted by the HIV and used to generate new viruses, thereby causing 
the depletion of the CD4 cells. The body becomes prone to opportunistic infections as in 
the orofacial region where some specific infections indicate diminishing immunity 
(Ceballos-Salobrena at al 2000; Vaseliu et al, 2006). A CD4 cell count of <200cells/mL 
defines AIDS (CDC-Classification, 1993), and used as the basis to commence HIV-
infected individuals on HAART in poor resource countries. The CD4 cells increase with 
the use of HAART. Umadevi et al (2007) noted an increase from 241cells/mL at first 
visit to 416cells/mL after 9months. The newly formed cells have compromised 
immunocompetency as proven by the existence of some oral lesions in individuals on 
HAART as the increase in oral warts SGD as well as hyperpigmentation (Frezzini et al, 
2005; Miziara and Weber, 2006; Hodgson et al, 2006). 
 
2.5.2 Viral load count 
 
The amount of viruses in the blood is also used to determine the severity of the infection 
by clinicians.  HAART reduces the viruses in circulation; in turn more CD4-cells mature 
and fight infections better (Tappuni et al, 2001; Greenspan et al, 2004; Nicolatou-Galitis 
et al, 2004; Hodgson et al, 2006). However in Zimbabwe viral load counts are omitted 
due to prohibitive costs. 
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2.6 HAART, Oral lesions and IRIS 
 
Immune reconstitution inflammatory syndrome (IRIS) occurs when the CD4 cells raises 
to >500cells/ml of blood and a viral load below the detectable levels through the use of 
HAART. Severe opportunistic infections resurface in contrast to the generally reported 
decrease in such conditions when HAART is employed.  
 
Oral candidiasis is one such condition, which has been reported in individuals with IRIS 
(Gaitan Cepeda et al, 2008). Corti and co-researchers in 2007 defined the diagnosis of 
non-Hodgkin’s lymphoma of the oral cavity as an IRIS condition in a patient with CD4 
cell count of 198/ml and undetectable viral load. These studies highlighted the existence 
of oral lesions (OLs) in IRIS condition and suggest for the inclusion of OLs in the 
conditions associated with IRIS. 
 
2.7 HAART and most common Oral Lesions 
 
2.7.1 General response of oral manifestations to HAART 
 
HAART significantly reduces the prevalence and severity of opportunistic infections 
including orofacial lesions in HIV infected individuals (Tappuni et al, 2001; Miziara et 
al, 2006; Hodgson et al, 2006; Umadevi et al, 2007). Ceballos-Salobrena et al (2000) 
reported a decline of 30%. Parveen et al (2007) and Hamza et al (2006) found no changes 
among adults and children respectively. 
 
Oral warts increased in patients on HAART (Greenspan et al, 2001). Hamza et al (2006) 
and Umadevi et al (2007) noted an increase in hyperpigmentation. After at least 6months 
on HAART, a more favourable response was reported in patients who received HAART 
including effavirenz than HAART and protease inhibitors, 32% and 63% respectively 
(Aquino-Garcia et al, 2008).  
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2.7.2 Fungal infections 
 
Oral candidiasis (OC) represents the most prevalent opportunistic infection in HIV- 
infected individuals.  The prevalence is estimated to be 70% to 90%. It appears relatively 
early and the recurrence rate and severity are used as markers of progression into AIDS 
(Scully, 2004; Vasiliu et al, 2006). The three commonest types are Psuedomembranous 
candidiasis (PC), Erythematous Candidiasis (EC) and Angular Cheilitis (AC). PC the 
most prevalent, indicate very low CD4-cell count and very high viral load. The second 
most common is EC. AC is dominant in children. A significant reduction in the 
occurrence of these lesions through HAART has been reported by Greenspan et al 
(2004). PC and EC dropped from 6.70 to 2.85% and 5.48 to 2.99% respectively. 
Similarly Umadevi et al (2007) reported OC at first visit and after 3months and none at 6 
and 9 months in patients on HAART.  
 
EC is more prevalent in patients on HAART and those with IRIS than PC (Gaitan Cepeda 
et al, 2008; Aquino-Garcia et al, 2008). Oral candidiasis is also used in WHO 
classification and staging of HIV infection. Recent studies are pointing at the presence of 
OC in patients on HAART after 3 months as a sign of treatment failure (Flint et al, 2006; 
Ramirez-Amador et al, 2007). This could be used by clinicians especially in poor 
resource settings to monitor response in patients on HAART, instead of relying on costly 
immunological parameters. 
 
2.7.3 Bacterial infections 
 
This category has 3 forms of lesions, necrotising ulcerative gingivitis (NUG), necrotising 
ulcerative periodontitis (NUP) and linear gingival erythema (LGE). Periodontal diseases 
are earliest signs of HIV- infection (Winkler et al, 1998). The prevalence of periodontal 
diseases ranges from 0-47% in adults and 0-20% in children (Frezzini et al, 2005). 
Eyeson et al (2002) registered NUG decline from 8% to 2%. The oral hygiene conditions 
and smoking adversely affect these bacterial infections (Kroidol et al, 2005; Frezzini et 
al, 2005).  
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2.7.4 Viral infections 
 
2.7.4.1 Herpes Simplex Virus (HSV 1) infection 
 
Vaseliu et al (2006) noted a prevalence of 10-35% in both adults and children.  A decline 
from 2.9% to 0% in prevalence of HSV-1 infection with HAART was reported by 
Schmidt -Westhausen et al (2000).   
 
2.7.4.2 Herpes Varricella Zoster (HVZ) infection 
 
The infection is caused by reactivation of the latent chicken pox virus and seldom seen in 
adults and children. The trigeminal nerve is affected to 15-20% of patients (Laskaris, 
1996). In Zimbabwe, Jonsson et al (1998) reported prevalence of 12%.  Nicolatou-Galitis 
et al (2004) reported 1 patient on ART. Any association with low CD4 cell count has not 
been concluded.  
 
2.7.4.3 Oral hairy leukoplakia (OHL)  
 
OHL is believed to be caused by EBV. It dominates in adults than in children, with 
prevalence of 20-25% and 2-3% respectively (Vaseliu et al, 2006). Arendorf and Holmes 
(2000) noted a prevalence of about 6% in Africans and 26% in Americans and 
Europeans. Schmidt-Westhausen et al (2000) reported 65% MSM and reported no OHL 
at second evaluation. Sroussi et al (2007) reported after 6months a four fold increase in 
prevalence of OHL in smokers compared to non-smokers, 12.1% and 3.4% respectively. 
 
2.7.4.4 Human Papilloma Virus (HPV) infection (Oral warts, OWs) 
 
The infection was a rarity before the advent of PIs. In HIV negative and positive 
individuals, the prevalence reported by Frezzini et al (2005) were 7.6% and 25.3% 
respectively. Greenspan et al (2001) had noted 5% OWs in persons on and not on ART, 
23% were on HAART (P=0.01).  
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There is dominance among men having sex with men (MSM) who practise oral sex. HPV 
has been implicated as the cause of oral squamous cell carcinoma (Frezzini et al, 2005; 
Hodgson et al, 2006).  
 
2.8 Malignancy 
 
2.8.1 Kaposi's sarcoma (KS) [HHV-8: Human Herpesvirus 8 infection 
 
The lesion is recognised as the commonest neoplasm in individuals with HIV-infection 
and is caused by HHV 8.  In Zimbabwe, Jonsson et al (1998) reported 72% of the patients 
with oral KS with male predilection. Low CD4-l count and high viral load are risk 
factors. KS is an AIDS condition according to WHO clinical staging. HAART has direct 
anti-tumour activity from PIs. 
 
2.8.2 Non-Hodgkin Lymphoma (NHL) 
 
It is the second most prevalent tumour in HIV- infected persons, and is an AIDS defining 
condition (EC Clearinghouse Classification, 1993; CDC, 1993). The condition is of dual 
infection with EBV and HHV-8. It appears more in children. Chidzonga (2003) reported 
7.1%. HAART reduces the prevalence of NHL as noted by Naidoo (2001). 
 
2.9 Salivary Gland Disease (SGD) and Xerostomia 
 
SGD presents as benign hypertrophy of the parotid glands, with a prevalence in children 
of between 10-30% (Naidoo and Chikte, 2004). Frezzini et al (2005) reported a 
prevalence of 3-10% in adults. Most HAART studies show an increase in prevalence. 
Ceballos-Salobrena et al (2000) found a rise in SGD from 0.9 to 4.5% associated with 
high viral load. Associated xerostomia can be an adverse effect of NRTIs (ddI, ddC) and 
PIs. Differential diagnosis should exclude use of antidepressants, tumours and Sjogren 
Syndrome especially in women. Reduced saliva flow increases the risk of developing 
caries and periodontal diseases. 
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2.10 Oral ulcerations 
 
There are recurrent aphthous ulcerations (RAU) and non-recurrent ulcerations (NRU). 
RAU responds to steroid therapy unlike the NRU. Major ulcers cause discomfort in 
mastication, speech and dysphagia. Eyeson et al (2002) reported almost similar 
prevalence for RAU in patients on ART (24%) and non- HAART (22%). Visalia et al, 
2006 mentioned severe RAU as a marker of CD4- count of <100. Recurrent oral 
ulcerations can have a prevalence of up to 30% in patients on zalcitabine as side effects 
as mentioned by Hodgson et al (2006). Oral ulcerations have been reported in individuals 
with Behnet’s disease in HIV/AIDS (Mahajan et al, 2005). 
 
2.11 Mucosal Hyperpigmentation 
 
Melanosis is found in HIV/AIDS patients increasing with the use of HAART. Zidovudine 
use is also implicated (Hodgson et al, 2006). In 2006, Hamza et al found the condition to 
be the second most prevalent as did Umadevi et al (2007), who reported 14.8% and 
43.8% in non-HAART and HAART patients respectively. 
 
2.12 Molluscum contagiosum 
 
The condition is found in patients with AIDS and CD4 count <200. A CD4- count of <50 
causes numerous facial lesions, thus interfering with aesthetics. The recurrence rate is 
high. HAART and a raised CD4- count eventually eradicate the lesions. (Naidoo, 2001; 
Kekitinwa and Schwarzwald, 2006). 
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CHAPTER THREE: RESEARCH METHODOLOGY 
3.1  Introduction 
 
This chapter discusses the aims and objectives of the study as well as its research design 
and methodology. It discusses the study population and sampling and gives consideration 
to the methodology used by other researchers that had done similar studies. It also 
describes the development of the research instrument as well as the research method. Oral 
manifestations of HIV-infection are a common presentation in HIV/AIDS patients. Their 
frequency and severity increases with the deterioration of the immune system. The advent 
of Highly Active Antiretroviral Therapy (HAART) has led to the decrease in prevalence 
of most opportunistic infections including oral lesions. The effect of HAART on the 
prevalence of oral lesions has been investigated elsewhere and in the African region in 
Nigeria (Olaniyi et Sunday, 2003) and Tanzania (Hamza et al, 2006). In Zimbabwe some 
studies were done prior to the era of HAART by Jonnson (1998) and Chidzonga (2003). 
The availability of HAART in Zimbabwe forms the foundation of this study, which shall 
be comparable with other global studies. 
 
3.2  Aims and Objectives 
 
The aim of the present study was to determine the prevalence of oral lesions in patients 
before and after undergoing HAART 
 
The broad objective was to describe the effect of HAART on oro-facial lesions in 
Zimbabwean HIV/AIDS patients at baseline, 3 and 6 months.  
 
The specific objectives were to determine the: (i) demography of the sample (ii) 
prevalence of oral lesions at baseline, 3 and 6 months and (iii) the relationship between 
CD4 counts and oral lesions 
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3.3  Study site  
 
Zimbabwe is in both the eastern and southern hemispheres. It is a landlocked country 
covering 390,624 sq km and is positioned in southern Africa, and bordered by the 
countries of Botswana, Namibia, Zambia, Mozambique and South Africa. It has a 
population of 12 360 000. Harare is the capital. It is the most populous city in the 
country, though physically the smallest. It has a population of over 1 533 190 million 
people. Eighty per cent of the population reside in rural areas of the state.  
 
Figure 1: Map of Zimbabwe (Courtesy: www. nationalgeographic.org) 
 
 
Table 1: Population distribution of Harare (2008 estimates) 
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Harare is the nation’s commercial centre due to the numerous banks and financial 
institutions situated there. There are 10 clinics, 17 primary health care centres, 12 
polyclinics, 2 infectious disease hospitals and 2 tertiary health facilities in Harare. 
 
These 33 institutions constitute the public health sector in Harare. The private sector 
comprises of 5 hospitals, 350 surgeries, 10 maternity homes, 8 nursing homes, 83 dental 
surgeries, 39 physiotherapy clinics, 60 medical laboratories of which 11 are public 
institutions, 36 ophthalmic/optic centres, 18 radio diagnostic centres and  10 ambulance 
services, 91 pharmacies, 4 natural therapy clinics. To manage these private and all public 
institutions in the country are 905 medical practitioners, 82 dental practitioners, 53 dental 
therapists, 1 dental hygienist, 4 maxillo-facial surgeons, 1 periodontist, 1 oral pathologist, 
1 orthodontist and 10 dental technicians. It is obvious that the dental and medical 
practitioners are too few to efficiently and effectively administer the health services in 
Zimbabwe and greater Harare. 
 
 
3.4 Study design 
 
The study design was longitudinal and descriptive, investigating the prevalence of oral 
lesions presenting in HIV/AIDS patients at baseline, 3 and 6 months after taking 
HAART. 
 
CATEGORY NUMBER PERCENTAGE 
Male  769 043 50.1 
Female  764 147 49.9 
Total  1 533 190 100 
   
Children<5yrs    203 528 13.3 
Children 5-14yrs    285 631 18.6 
15-64yrs 1 011 661 66.0 
 >65yrs    32 370 2.1 
Total  1 533 190 100 
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3.5 Research strategy  
 
The research consisted of both quantitative and qualitative elements. The latter involved 
the diagnosis of the lesions and the quality of life information. The medical history 
identified opportunistic infections that are associated with HIV/AIDS. Quantitative data 
included the age of the participants and the CD4 counts. Furthermore, the main aim of 
research requires the quantitative analysis of the data. 
 
3.6  Instrument used 
 
A data capture sheet was used as the tool for entering the data during the study. The basic 
format was adopted from the UWC, the Department of Community Dentistry and 
modified by the researcher, the Principal Investigator (PI). The data capture sheet was 
designed for recording information necessary for the study design adopted (Appendix 
III).  
 
The data captured was grouped into the following categories: 
 
Demographic information 
The demographic information included the identity of the participants, which was 
subdivided into groups that included the age, gender, the project code number, the 
hospital code number and the patient hospital number. 
 
Medical history 
Medical history from records and the patients including smoking: Conditions noted 
included TB, STIs, Herpes zoster, Oral thrush, Meningitis- cryptococcal, severe 
persistent rash, 10% loss of weight, prolonged diarrhoea, persistent fever and others. 
 
Physical examination 
• Physical examination for the diagnosis of lymphadenopathy and salivary gland 
function. 
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• The appearance of the marginal gingivae according to Loe and Silness, 1963. 
• Oral mucosa included the orofacial lesions associated with HIV infection and their 
location as on the lesion report form: fungal, bacterial and viral infections, oral 
ulcerations and neoplasm. The conditions were reported at baseline, 3 months and 6 
months. 
 
HIV status 
• The HIV status from records: parameters reported included: the type of HIV test 
done, date of HIV test, the mode of transmission, the WHO clinical stage, the CD4- 
cell count and date taken. The CD4 count was also noted at 6 months. 
 
Therapy 
• Cotrimoxazole prophylaxis: date commenced and stopped. 
• HAART treatment combinations: first line and second line regimen available in 
Zimbabwe. 
• Treatment of oral lesions: current antimycotic, antibacterial prophylaxis and others 
and lastly 
 
The Quality of life information: 
• Past and current history of oral problems ranging from the type of lesion from the 
perception of the participant, when it happened, duration of pain or discomfort and 
difficulties encountered.  
The description of the oral function, capturing dysphasia, xerostomia, taste 
alterations, dental caries and periodontal disease experiences and sleep disturbances. 
 
3.7  Selection of study population 
 
The study population consisted of patients with HIV recruited from the Opportunistic 
Infection Clinics (OICs) at Wilkins Infectious Disease Hospital (WIDH), Beatrice Road 
Infectious Disease Hospital (BRIDH) and Parirenyatwa Pediatric Opportunistic Infection 
Clinic (PPOIC). These City of Harare and Government hospitals have been mandated to 
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initiate HAART. Patients are started on HAART and reviewed monthly for re-supply of 
drugs by OIC Clinicians. The participants were selected in November 2007 through to 
January 2008 and reviewed from February to July 2008 from Opportunistic Infection 
Clinics (OICs) at BRIDH, WIDH and PPOIC. BRIDH and WIDH belong to the City of 
Harare while PPOIC is government owned.  
 
HAART is defined as a combination of 2 Nucleoside Reverse Transcriptase Inhibitors 
(NRTIs) and 1 Protease Inhibitors (PIs) with or without 1Non Nucleoside Reverse 
Transcriptase Inhibitors (NNRTIs). ART comprises of 2 NRTIs and 1 NNRTI.In this 
study HAART is synonymous with Antiretroviral Therapy (ART). The participants 
booked for initiation of HAART were first examined by the OIC doctor and put on 
HAART then referred to the principal investigator (PI) AM, a dentist in a separate 
consultation room for extra- and intra-oral assessment. The examination followed after 
the signing of the consent form (Appendix 1). A junior dentist assisted in recording the 
findings on a data capture sheet (Appendix II). Examinations were conducted on 
individual basis under strict confidentiality. A pilot study (October, 2007) was done at 
BRIDH and PPOIC.  
 
Referrals to specialists were facilitated through the OI clinicians. A statistician together 
with the PI analyzed the results of the study. Permission was sought and obtained from 
relevant authorities namely the Medical Research Council of Zimbabwe, City of Harare 
and Parerenyatwa Group of Hospitals. 
 
Inclusion criteria were: 
 
• Confirmed HIV positive patients willing to participate and providing informed 
consent 
• HIV patients not on HAART before 
• HIV positive with a CD4 cell count <200 cells/mL of blood 
• HIV positive children (<18 years) with CD4 percent of <25% 
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Exclusion criteria were: 
• Very ill patients, unable to give consent and  
• In- patients 
 
3.8 Sample size 
A convenience sample of 210 patients with HIV were enrolled at baseline. 
 
3.9 Measurement 
 
This study employed the use of a structured data capture sheet. It collected demographic 
information. It tried to ensure that it suited the aim and objectives of the study and was 
simple, clearly understood and unambiguous. Planning of the questionnaire began in 
February 2007. It was designed following discussions with academics and other dental 
professionals working in the field and was based on the following: 
• It suited the aim of the study 
• It suited the nature of the participants 
• It was clear, simple, unambiguous 
• The design minimized potential errors from principal investigator and coder 
• The subject of the questionnaire was of interest to the participants, and hopefully 
encouraged their co-operation and elicited truthful answers 
• Well worded questions were essential, and pitfalls were avoided, for example, 
‘double-barrelled questions’ that is, when two questions are included in one- the 
questions were separated so that the respondent and the researcher can distinguish 
between the two. 
• The wording of the questions did not lead the respondent to feel obliged to answer in 
a particular way, which may not be truthful 
• Questions did not alienate either the respondent nor the researcher 
• Efficient and meaningful analysis of the acquired data should have been possible. 
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3.10  Pilot study 
 
A pilot study was done on 6 patients in October 2007 at BRIDH and PPOIC. The process 
tested the suitability and adequacy of the data capture sheet for the study. The 
information collected was supposed to allow the aim and objectives of study to be met. 
Any unnecessary items were omitted. It also provided an estimate on the time taken to 
carry out one interview. 
 
3.11 Final draft preparation 
 
After the piloting, irrelevant and unclear questions were identified and either deleted or 
appropriately modified. Question 4 was added to enable follow up of patients who were 
referred to their local clinics for reviews. Included also were the quality of life 
information.  This improved the efficiency of the data capture sheet and reduced the time 
planned per interview. At the end, a total of 16 questions were printed for the main study. 
 
3.12  Data collection 
 
The participants were conveniently selected consecutively for 3 months from BRIDH, 
WIDH and PPOIC. The principal investigator (AM) informed the participants in their 
language of choice (English, Shona) about the study and invited them to participate on 
voluntary basis. The patients were assured of strict confidentiality and the provision for 
opting out at any time without penalties, before signing the consent form. Medical history 
information was taken from the medical records.  
 
The participants were examined while seated on an ordinary chair at WIDH and PPOIC. 
At BRIDH they were sitting on dental chairs in the dental department. A physical 
examination was then undertaken, extra orally first, with palpation of the head and neck 
region followed by the oral examination.  
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Extra-oral assessment involved palpating cervical lymph nodes and the parotid glands 
and other visible swellings including skin lesions. Mouth mirrors were used and extra 
light from a torch for intraoral examination. A systematic examination was used as 
provided in the oral mucosa assessment manual (Appendix III). 
 
3.13 Oral examination 
3.13.1 Oral mucosa - Examination procedure 
An examination of the oral mucosa and soft tissues in and around the mouth was made on 
every subject. Any abnormalities of the mucosa or of the gingiva were reported on the 
chart on the data capture sheet (Roed-Petersen and Renstrup, 1969). In addition, a full 
description of the lesion’s size, shape, type and anatomical site was documented. If the 
cause of the lesion was obvious it was noted.  
 
The examination was thorough and systematic and was performed in the following 
sequence: 
(i) Labial mucosa and labial sulci (upper and lower) 
(ii) Labial part of the commisures and buccal mucosa (right and left) 
(iii) Tongue (dorsal and ventral surfaces, margins) 
(iv) Alveolar ridges/gingiva (upper and lower) 
(v) Floor of the mouth 
(vi) Hard and soft palate 
 
Two mouth mirrors were used to retract the tissues. The following procedure was used 
and the following codes were used to record the absence, presence or suspected presence 
of the condition: The lips were examined with the mouth closed and open. The colour, 
texture and any surface abnormalities of the vermillion border were noted. The mandible 
vestibule was examined visually with the mouth partially opened. The colour and any 
swelling of the vestibular mucosa was reported. The maxillary vestibule and fraenulum 
with the mouth partially opened was examined. Using the plane mouth mirrors as 
retractors and the mouth wide open, the entire buccal mucosa extending from the 
commisures and back to the anterior tonsillar pillar was examined.  
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With the tongue at rest and the mouth partially opened the dorsum of the tongue was 
inspected for any swelling, ulceration, coating or variation in colour or texture. The 
patient was then asked to protrude the tongue and the examiner noted any abnormality of 
mobility. The margins of the tongue were inspected with the aid of the mouth mirrors and 
then the ventral surface was reported. While the tongue was still elevated, the floor of the 
mouth was inspected for swellings or any other abnormalities. With the mouth wide open 
and the subject’s head tilted backwards, the base of the tongue was gently depressed. The 
hard palate was inspected first followed by the soft palate. Any mucosal or facial tissues 
that seemed to be abnormal, as well as the submandibular and cervical lymph nodes, were 
palpated. The criteria used for diagnosis of oral mucosal lesions can be found in 
Appendix III. 
 
3.14  Standardization and calibration 
 
The objectives of the standardization and calibration exercises are to: 
(i) ensure uniform interpretation, understanding and application of the criteria 
            for the various diseases and conditions that were reported and reported. 
(ii) ensure that each examiner could examine consistently to a standard. 
(iii) minimize variations between different examiners. 
 
3.14.1 Intra-examiner calibration 
 
The principal investigator (AM) carried out the extra-oral and intra oral examinations. 
This promoted the maintenance of consistency through out the study. She also conducted 
the interview on the quality of life. 
 
3.14.2 Inter-examiner calibration 
 
At the start of the study, the PI (AM) carried out extra-oral and intra-oral examinations on 
10% of the participants. An experienced oral pathologist was engaged in the triangulation 
process. The principal investigator would examine the participant first, then the 
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pathologist independent of each other. The results of the examinations would be 
compared and if the there was disagreement, the patient was re-examined by both 
examiners. The pathologist was disengaged when agreement of diagnosis reached 85- 
90%. By comparing the results of the two examinations on the same participant, the PI 
was able to obtain an estimate of the extent and nature of the diagnostic errors. 
 
3.15 Follow-up strategy 
 
• Participants had to attend for HAART follow up at 3 and 6 months and the oral 
examination and follow up will take place at the same visit. 
• 2 months after the first assessment, a remainder was written in their hospital files 
about the re-examination on their next visit to the OIC and the OIC-clinicians 
advised also to emphasise this when the examined them. 
• The principal investigator phoned the participants to remind them of the re-
examination dates. 
• Furthermore, reminders were hand delivered to the participants through the 
Department of Health Education and Promotion, City Health at 5 months. 
• The postal services were excluded due to its current unreliability. 
• The original sample size of 200 was increased by 5% to cater for drop-outs. 
• The examiner took unpaid leave in April, June and July 2008 to consolidate follow-
ups. 
 
3.16  Data analysis 
 
The data was entered on the data capture sheet (Appendix II). Descriptive statistics were 
used to summarize socio-demographic factors and other variables. Prevalence of oral 
lesions was determined by calculating the percentage ratio of patients presenting with 
OLs. Frequency tables were used to summarize and identify the most common oral 
lesions. Multiple linear regressions were carried out to identify factors (socio-
demographic, presence of OLs, period on HAART) that were significant in predicting 
CD4-cell count.  
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Multiple logistic regressions were performed to identify socio-demographic factors that 
are significant in predicting presence of oral lesions. Chi-square test was done on 
qualitative socio-demographic factors to determine factors that are statistically associated 
with presents of OLs. Odds ratio and 95% Confidence intervals were also be calculated. 
Questionnaire data were categorized, coded and entered into the computer. Epi-info 
version 3.2 was employed in the statistical analysis of the data. 
 
3.17 Ethical considerations 
 
3.17.1 Establishing contacts 
 
Access to participants was sort initially by letter to the participating hospitals through the 
A/Director of City Health Department and Clinical Director Parerenyatwa Group of 
Hospitals. An introduction of the researcher, basic aims, objectives of the study and the 
time frame was explained. Emphasis was made on strict confidentiality and assurance of 
anonymity in the presentation of study results. Once a signed consent form was received 
from each participant, the clinical examination was carried out during hospital schedules. 
The participants signed the consent form translated into Shona for easy understanding. 
 
3.17.2.  Ethical considerations 
 
The protocol was submitted and approved by the Research Ethics Committee of the 
University of the Western Cape for ethical approval (see attached copy). Permission from 
the A/ Director of Health Services for Harare City and Clinical Director of Parerenyetwa 
Group of Hospitals was obtained to access participants at the various hospitals. The 
research commenced after authorization by the Medical Research Council of Zimbabwe. 
Informed consent in his or her language of choice (Shona or English) was obtained from 
each participant. 
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Participants were referred (if specific treatment and other interventions were required) to 
the Gershon Dental Clinic, BRIDH. Referrals to specialists were provided accordingly 
through the OIC clinicians. Furthermore, each participant received an individual oral 
health report within 3 months of completing the survey with appropriate advice. The 
participants were advised to take their individual reports to their private dental 
practitioners or to seek alternative treatment at the dental school or nearest dental clinic. 
 
3.19 Conclusions 
 
The study was a descriptive longitudinal study on HIV/AIDS patients in Harare. It aimed 
at a population sample of 210 and utilized a data capture sheet which was analyzed using 
Epi-info version 3.01. 
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CHAPTER FOUR: RESULTS 
 
4.1 Introduction 
 
One of the problems associated with longitudinal study designs is the inability to follow 
up participants to the end of the study. The present study was carried out at one of the 
worst periods in the political stage in Zimbabwe – during the highly contested and violent 
national elections. The response to follow up in this present study was very much 
affected by sociopolitical factors at play during this period. Furthermore, health care 
workers prolonged the recruitment period and minimized the initiation of patients on 
HAART during this challenging period. Consequently, the follow-up rate was 
tremendously reduced during the election period in March and subsequently June 2008 
due to the violence and fact that many people had fled the country and it was impossible 
to contact all the participants in time for their 6 month follow-up. In Zimbabwe, the 
standard protocol for CD4 counts dictates that they can only be taken at 6months 
intervals. 
 
4.2  Final Response rate 
 
A convenience sample size of 200 participants was targeted. 210 HIV positive patients 
participated at baseline. At 3 months, 96 (46%) and at 6 months, 52 (25%) were available 
for review respectively. 
 
4.3 Demographic data 
 
At baseline 210 HIV positive patients were recruited into the study from three hospitals 
(Table 2). Two infectious disease hospitals belonged to the City of Harare and the other is 
a government hospital. Just over two thirds were female (64.3%) and the age ranged as 
follows: 31-40 (44%) years of age followed by 41-50 (26%) then 21-30 (17%) and 51-60 
(9%). The minimum age at baseline was 3.0 years and maximum 83.0 years, with a mean 
age of 38.3years (S.D 10.3). 
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Table 2: Study sites and Gender Characteristics  
Variable Frequency Percent 
Hospital 
Beatrice Road Infectious Disease Hospital 184 87.6 
Wilkins Infectious Disease Hospital 24 11.4 
Parirenyatwa Opportunistic  Infection Clinic 2 1.0 
Gender 
Female 135 64.3 
Male 75 35.7 
 
4.4 HIV Tests, Route of transmission, Cotrimoxazole prophylaxis, Year CD4 
count taken 
 
The participants were diagnosed HIV positive from the year 2004 through to 2008, with 
the majority 87.62% (184) diagnosed in 2007 and 9.05% (19) in 2006 (Table 3). Rapid 
HIV testing was mostly used for the confirmation of the HIV. The predominant means of 
transmission was sexual in heterosexual relationships followed by vertical transmission. 
The majority of the patients (84.76%) were in the WHO clinical stage 3 and 11.43% in 
stage 4. CD4-cell counts were taken in 2007 (98%). 186 participants were started on 
either Cotrimoxazole or fluconazole prophylaxis in 2007 and 12 in 2006. The rest (12) 
were commenced on the prophylaxis in 2000 (1), 2004 (1), 2005 (6) and 2008 (4). 
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Table 3: HIV Tests, Route of transmission, Cotrimoxazole prophylaxis, Year CD4 
count taken 
 
Variable Freq % 
Year of HIV Diagnosis 
2004 1 0. 48 
2005 2 0.95 
2006 19 9.05 
2007 184 87.62 
2008 4 1.90 
HIV Test Method 
Elisa 6 3 
Rapid 204 97 
Route Of Transmission 
Sexual 202 96.19 
Unknown 3 1.43 
Vertical 5 2.38 
WHO Clinical Stage 
1 1 0.48 
2 7 3.33 
3 178 84.76 
4 24 11.43 
Year of CD4 Count was taken 
2007 205 98 
2008 5 2 
Year started on Cotrimoxazole / fluconazole  
2004 1 0. 5 
2005 6 3 
2006 12 6 
2007 186 88 
2008 4 4 
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4.5 Medical history conditions 
 
The most prevalent medical condition was loss of weight which affected more than two 
thirds of them. Sexually transmitted infections contributed 66% followed by oral thrush 
at 58%. Other common conditions experienced were herpes zoster (35%), severe 
persistent rash (33%) as well as cryptococcal–meningitis (10%). There were no active 
smokers at the time of the study, but 24% used to smoke (Table 4). The most frequent 
condition was cervical lymphadenopathy which affected 40% of the patients followed by 
8% with parotid swelling and the least 2% had xerostomia.  
 
4.6 Appearance of marginal gingivae 
 
More than two thirds (68%) had varying degrees of gingival inflammation ranging from 
4% to 24%. A third at baseline presented with a normal gingival. Mild gingivitis followed 
by a distinct red band from papilla to papilla affected 24% and 22% of the participants 
respectively. Only 4% presented with severe gingival inflammation (Table 4).  
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Table 4: Medical history and oral examination  
Variable 
N=210 
Yes % 
Medical History Condition 
1. Tuberculosis 101 48 
2. STI 138 66 
3. Herpes Zoster 74 35 
4. Oral Thrush 121 58 
5. Meningitis-cryptococcal 10 5 
6. Severe persistent rush 69 33 
7. >10% loss of weight 147 70 
8. Smoking 51 24 
Physical exam lymphadenopathy & Salivary Glands 
Lymphadenopathy 83 40 
Parotid gland swelling 9 4 
Xerostomia (Dry mouth) 2 1 
Appearance of marginal gingivae (Loe & Silness, 1963) 
Normal gingiva                                                                               68 32 
Mild marginal gingivitis, slight colour change and oedema 51 24 
Moderate gingival inflammation, redness and glazing 36 17 
A distinct red band along the marginal gingiva  46 22 
Severe inflammation, marked redness and oedema, with ulceration 9 4 
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4.7 Oro-facial lesions at base line, 3 months and 6 months 
 
Table 5 shows the prevalence of oro-facial manifestations at baseline, 3 months and six 
months. 
 
Table 5: Oro-Facial Lesions: Overall baseline, 3 months and 6 months 
 
Lesion 
  
Baseline 3 months 6 months 
n=210 n=96 n=52 
Yes % Yes % Yes % 
Any Lesion 176 84 61 64 31 60 
Oral candidiasis       
Pseudomembraneous candidiasis 59 28 6 6 2 4 
Erythematous candidiasis 54 26 6 6 1 2 
Rhomboid glossitis 18 9 1 1 0 0 
Hyperplastic candidiasis 1 0.5 1 1 0 0 
Angular cheilitis 24 11 8 8 0 0 
Hairy leukoplakia 43 20 10 10 3 6 
Oral ulcerations       
Herpetic ulceration 12 6 6 6 3 6 
Aphthous ulceration 10 5 3 3 0 0 
Atypical ulceration 6 3 0 0 0 0 
Periodontal diseases       
Necrotizing ulcerative gingivitis 9 4 0 0 0 0 
Necrotizing ulcerative Periodontitis 3 1 3 3 0 0 
Linear gingival erythema 3 1 1 1 0 0 
Salivary gland disease       
Parotid gland enlargement 9 4 2 2 5 10 
Xerostomia 2 1 0 0 0 0 
Ranula 1 0.5 0 0 0 0 
Kaposi's sarcoma 5 2 1 1 0 0 
Non-Hodgkin Lymphoma 0 0 0 0 0 0 
Oral warts 2 1 0 0 0 0 
Mucosal Hyperpigmentation 13 6 16 17 6 12 
Molluscum contagiosum 19 9 7 7 3 6 
Herpes zoster 10 5 0 0 0 0 
Others       
Fissured depapilated tongue 8 4 0 0 0 0 
Hairy black tongue 4 2 0 0 0 0 
Tonsillitis/pharyngitis 4 2 0 0 0 0 
Herpetic ulceration healed 34 16 0 0 0 0 
Ringworms/facial rash 15 7 9 9 5 10 
Facial palsy 3 1 0 0 0 0 
Planar warts 6 3 21 22 10 19 
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Oral candidiasis 
 
At baseline, 176(84%) participants had 375 orofacial lesions. Oral candidiasis was the 
most predominant condition clinically diagnosed contributing 74% (156) (Table 5). 
Intraorally, erythematous candidiasis including median rhomboid glossitis 34% (72) was 
the most frequent condition followed by pseudomembranous candidiasis at 28% (59) then 
angular cheilitis 24 (11%) and hyperplastic candidiasis 1 (0.5%). Hairy leukoplakia 
affected 20% (43). 
 
Oral ulcerations 
 
Herpetic ulcerations were reported in 6% (12) of the patients while 16% (34) had healed 
lesions. Aphthous ulcers and atypical ulcers affected 5% (10) and 3% (6) respectively. 
 
Periodontal diseases 
 
Periodontal lesions presented in 15 participants in the following order: necrotizing 
ulcerative gingivitis 4% (9), necrotizing ulcerative periodontitis and linear gingival 
erythema 1% (3) each. 
 
Salivary gland disease 
 
The most prevalent condition was parotid gland enlargement found in 4% (9). 
Xerostomia was diagnosed in 1% (2) and ranula in 0.5% (1). 
 
Other common intra-oral and extra-oral lesions 
 
Kaposi’s sarcoma was reported in 5 (2%) of the patients and melanosis affected 13 (6%).  
Among extraoral lesions, molluscum contagiosum 19 (9%) was the commonest lesion 
followed by and herpes zoster reported in 10 (5%). 
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Uncommon extraoral lesions 
 
Ringworms/facial rashes were found among 15 (7%) of the patients, 6 (3%) presented 
with planar warts and the least were 3 (1%) patients with facial palsy. 
 
4.8 Immunological status at baseline 
 
The CD4-cell count was 200cells/mL of blood or less, indicating that all the participants 
had AIDS. A mean value of 104.61cells/ml was determined for 208 patients. The 
standard deviation was 54.82. The minimum and maximum CD4-cell counts were 1 
cell/ml and 200 cells/ml of blood. Some 2 children had CD4 percent of 2% and 12% 
(Table 6). 
 
Table 6: Age and CD4 Counts (baseline and at 6 months) 
 
Variable N Mean 
Std 
Dev Minimum Maximum 
Age (Years) 210 38.31 10.25 3 83.03 
CD4 Count 
(Baseline) 208* 104.61 54.82 1 200 
CD4 Count (6 mths) 52 211.98 132.67 7 742 
 
*2 children had CD4-percent: 2% and 12% (these were excluded when the mean CD4  
count was calculated) 
 
4.9 Oro-facial lesions after 3 months on HAART (n=96) 
 
Prevalence of Oral Lesions 
 
At 3 months on HAART, 96 participants were followed up (Table 7). 186 (65%) and 101 
(35%) lesions were identified at baseline and at 3 months respectively among the 96 
participants representing a 30% decrease (Table 7). Just over two thirds (61%) presented 
with 16 different oro-facial lesions.  
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Oral candidiasis affected 23% (22). Angular cheilitis was the most prevalent found in 8 
participants (8%) followed by erythematous candidiasis 7 (7%) including 1 case of 
rhomboid glossitis and pseudomembranous candidiasis 6 (6%). Only 1 (1%) person was 
diagnosed with hyperplasic candidiasis (1%).  
 
The second most common oral lesion was mucosal hyperpigmentation 16 (17%) followed 
by hairy leukoplakia 9 (9%). Other oral lesions were distributed as follows: herpetic 
ulcerations 6 (6%), aphthous ulcers 3 (3%), necrotizing ulcerative periodontitis 3 (3%), 
Kaposi’s sarcoma 1 (1%), linear gingival erythema 1 (1%). The most predominant 
extraoral lesions were facial planar warts (20%), ringworms/facial rash (9%) and 
molluscum contagiosum (7%). Parotid gland enlargement was reported in 2 patients 
(2%).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                    40 
Oral lesions in HIV/AIDS patients before and after HAART treatment.  
 
Table 7: Oro-facial lesions at baseline and 3 months (n=96) 
 
Lesion 
  
Baseline 3 months 
n=96 n=96 
Yes % Yes % 
Any Lesion 83 86 61 64 
Oral candidiasis 75 78 22 23 
Pseudomembraneous candidiasis 23 24 6 6 
Erythematous candidiasis 32 33 6 6 
Rhomboid glossitis 8 8 1 1 
Hyperplastic candidiasis 0 0 1 1 
Angular cheilitis 12 13 8 8 
Hairy leukoplakia 26 27 10 10 
Oral ulcerations 9 9 9 9 
Herpetic ulceration 3 3 6 6 
Aphthous ulceration 5 5 3 3 
Atypical ulceration 1 1 0 0 
Periodontal diseases 7 7 4 4 
Necrotizing ulcerative gingivitis 3 3 0 0 
Necrotizing ulcerative Periodontitis 1 1 3 3 
Linear gingival erythema 3 3 1 1 
Salivary gland diseases 6 6 2 2 
Parotid gland enlargement 6 6 2 2 
Xerostomia 0 0 0 0 
Ranula 0 0 0 0 
Kaposi's sarcoma 1 1 1 1 
Non-Hodgkin Lymphoma 0 0 0 0 
Oral warts 0 0 0 0 
Mucosal Hyperpigmentation 9 9 16 17 
Molluscum contagiosum 9 9 7 7 
Herpes zoster 8 8 0 0 
Others 36 38 30 31 
Fissured depapilated tongue 4 4 0 0 
Hairy black tongue 1 1 0 0 
Tonsillitis/pharyngitis 2 2 0 0 
Herpetic ulceration healed 18 19 0 0 
Facial palsy 2 2 0 0 
Ringworms/facial rash 6 6 9 9 
Planar warts 3 3 21 22 
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4.11 Oro-facial lesions at 6 months prevalence of oro-facial lesions  (n=52) 
 
At 6 months there were only 52 participants available for follow-up.  9 types of lesions 
were identified compared to 16 at 3 months and 26 oro-facial lesions at baseline (Table 
8). Oral candidiasis had decreased to a prevalence of 6%.  An outstanding finding was the 
increased prevalence of planar warts contributing 19% (10) followed by parotid gland 
enlargement and ringworms/facial rash with10% (5) each then the least was 6% (3) 
molluscum contagiosum. Considering only the 52 patients, at baseline there were 94 
(52.81%) lesions, at 3 months 46 (25.84%) lesions and at 6 months 38 (21.35%) lesions 
(Table 8). 
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Table 8: Oro-facial lesions at baseline, 3 months and 6 months (n=52) 
 
Lesion 
  
Baseline 3 months 6 months 
N=52 n=52 n=52 
Yes % Yes % Yes % 
Any Lesion 43 83 29 56 31 60 
Oral candidiasis 37 71 8 15 3 6 
Pseudomembraneous candidiasis 10 19 2 4 
 
2 4 
Erythematous candidiasis 17 33 1 2 1 2 
Rhomboid glossitis 5 10 1 2 0 0 
Hyperplastic candidiasis 0 0 1 2 0 0 
Angular cheilitis 5 10 3 6 0 0 
Hairy leukoplakia 8 15 3 6 3 6 
Oral ulcerations 5 10 3 6 3 6 
Herpetic ulceration 2 4 2 4 3 6 
Aphthous ulceration 3 6 1 2 0 0 
Atypical ulceration 0 0 0 0 0 0 
Periodontal diseases 2 4 0 0 0 0 
Necrotizing ulcerative gingivitis 2 4 0 0 0 0 
Necrotizing ulcerative Periodontitis 0 0 0 0 0 0 
Linear gingival erythema 0 0 0 0 0 0 
Salivary gland diseases 5 10 2 4 5 10 
Parotid gland enlargement 5 10 2 4 5 10 
Xerostomia 0 0 0 0 0 0 
Ranula 0 0 0 0 0 0 
Kaposi's sarcoma 1 2 1 2 0 0 
Non-Hodgkin Lymphoma 0 0 0 0 0 0 
Oral warts 0 0 0 0 0 0 
Mucosal Hyperpigmentation 7 13 9 17 6 12 
Molluscum contagiosum 5 10 5 10 3 6 
Herpes zoster 5 10 0 0 0 0 
Other 19 37 15 29 15 29 
Fissured depapilated tongue 2 4 0 0 0 0 
Hairy black tongue 1 2 0 0 0 0 
Tonsillitis/pharyngitis 1 2 0 0 0 0 
Herpetic ulceration healed 9 17 0 0 0 0 
Facial palsy 1 2 0 0 0 0 
Ringworms/facial rash 3 6 6 12 5 10 
Planar warts 2 4 9 17 10 19 
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4.12 HAART combinations and treatment for oral lesions 
 
At the time of commencement on HAART at baseline, 11% (24) were taking antifungal 
and 1% (2) antibacterial medication. The HAART combinations used included 2 NRTIs 
(stavudine and lamivudine) and 1 NNRTI (nevirapine or efavirenz). The majority of 
participants 98% (205) were started on stavudine, lamivudine and nevirapine and only 
2% who were on anti-TB treatment received stavudine, lamivudine and efavirenz (Table 
9). Three months later, the most predominant combination of drugs was stavudine, 
lamivudine and nevirapine (95%; n=91). Four patients were on stavudine, lamivudine and 
efavirenz. Only 1 individual was taking zidovudine, lamivudine and nevirapine at the 
time of examination after 3 months on HAART. At 6 months the combination of drugs 
consisted of stavudine, lamivudine and nevirapine (83%); stavudine, lamivudine and 
efavirenz (2%) and zidovudine, lamivudine and nevirapine (15%). The third combination 
was not prescribed at baseline and only 1 participant had it at 3 months. None of the 
individuals was taking medication for the treatment of oral lesions at 3 and 6 months 
(Table 9). 
 
Table 9: Treatment combinations for first line regimen 
Combinations:  
Baseline 
(n=210) 
3 months 
(n=96) 
6 months 
(n=52) 
Yes % Yes % Yes % 
Stavudine + lamivudine + nevirapine 205 98 91 95 43 83 
Stavudine + lamivudine + efavirenz 5 2 4 4 1 2 
Zidovudine + lamivudine + nevirapine 0 0 1 1 8 15 
Zidovudine + lamivudine + efavirenz 0 0 0 0 0 0 
Treatment for oral lesions: Medication       
Antibiotic  2 1 0 0 0 0 
Mouthwash 0 0 0 0 0 0 
Antifungal  24 11 0 0 0 0 
 
 
 
 
 
 
 
                                                                    44 
Oral lesions in HIV/AIDS patients before and after HAART treatment.  
 
4.13 Quality of life information 
Quality of life information was only obtained at baseline and is reported below in Table 
10. 
 
Table 10: History of Oral Problems 
 
Question 
n=210 
Yes % 
Have you ever had any sores/ ulcers in your mouth? 102 49 
 
 
n=102 
Freq % 
a. If yes, what problem did you have? 
Discomfort 17 17 
None 0 0 
Pain 85 83 
b. When did you have them? 
1 to 3 months ago 36 35 
Currently having the problem 8 8 
Less than a month ago 23 23 
More than 3 months to 6 months ago 14 14 
More than 6 months ago 21 21 
c. Did they cause you pain or discomfort? (yes, n=102) 102 84 
• If Yes (n=102), please explain for how long 
1 to 2 weeks 63 62 
Less than a week 18 18 
More than 1 month 9 9 
More than 2 weeks to 1 month 12 12 
d. Are you having any pain or discomfort with your 
mouth now?  
74 35 
      *If Yes (n=74), is this pain /discomfort causing difficulty with:  
Eating 63 85 
Drinking 24 32 
Swallowing 17 23 
Speaking 9 12 
Working 1 1 
Sleeping 5 7 
   * More than one response was allowed   
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History of oral problems 
 
Nearly half of the participants reported having oral ulcers or sores and 83% reported 
experiencing pain. The duration of the pain or discomfort per episode was less than 7 
days for 17.64% to more than a month for 8.82%. The majority (61.78%; n=63) suffered 
pain for between 1 to 2 weeks. More than a third admitted having some pain or 
discomfort at baseline. The commonest difficulty was eating (85%; n=63) followed by 
drinking (32%; n=24). Swallowing was affected in just less than a quarter (23%) of 
patients. 
 
Table 10 presents the findings on the oral function at baseline (n=210). Nearly half (45%; 
n=94) experienced a painful throat either often (8%; n=16) or sometimes (37%; n=78).A 
third reported having difficulties in swallowing liquids (30%; n=63).   
 
More than half of the patients (55%; n=116) had suffered from xerostomia during the 
course of their illness and three quarters (76%, n=140) reported having problems with 
their sense of taste, with 27% (n=57) reported suffering from an altered taste often (Table 
10).  
 
Nearly three quarters (73%; n=154) of the participants experienced problems with their 
teeth. 120 (73%) patients had pain (106) and discomfort (14) during eating. Just under 
two thirds reported that their sleep was disturbed due to mouth problems. Just under 
twenty per cent reported having a dry mouth. 
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Table 11: Oral Function at baseline (n=210) 
Question Responses n=210 
Yes % 
Have you had a painful throat? Often 16 8 
Sometimes 78 37 
Never 116 55 
Have you had problems swallowing liquids? Often 14 7 
Sometimes 49 23 
Never 147 70 
Have you had problems swallowing solid food? Often 17 8 
Sometimes 54 26 
Never 139 66 
If Yes (n=94), when did you have them? 1 to 3 months ago 30 32 
Currently having the 
problem 11 12 
Less than a month ago 18 19 
More than 3 months to 
6 months ago 19 20 
More than 6 months 
ago 16 17 
Have you had a problem with a dry mouth Often 58 28 
Sometimes 58 28 
Never 94 45 
Have you had problems with your sense of taste? Often 57 27 
Sometimes 83 40 
Never 70 33 
Have you had problems with your teeth?  154 73 
If yes, explain (n=154) Food impaction 3 2 
Hypersensitivity 4 3 
Toothache 147 95 
Have you had trouble eating?  120 73 
If yes, explain (n=120) 
 
Discomfort 14 12 
Pain 106 88 
Have you had problems with your gums?  85 40 
If yes, please explain (n=85) 
 
Bleeding 43 51 
Halitosis 2 2 
Pain 40 47 
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Question Responses n=210 
Yes % 
Have any of your mouth problems stopped you from sleeping? 122 58 
If yes, please explain(n=122) 
 
Dry mouth 22 18 
Painful gums 7 5 
Sores/ulcers 1 1 
Toothache 92 75 
 
4.4 Immunological results at 6 months 
 
There were only 52 patients available for follow-up at 6 months, compared to 96 at 3 
months and 210 at baseline. The mean CD4 cell count was 211.98 at 6 months while at 
baseline it was 104.61 cells/ml of blood (Figure 2). At six months, 31 (59.62%) had CD4-
cell counts of less than 200, with 19 (36.54%) between 200-500 and only 2 (3.85%) had 
more than 500 cels/ml of blood (Table 12). 
 
In Table 13 the mean  differences in CD4- cell counts at 6 months and baseline were 
calculated, only for the 52 participants, using a bi-varient analysis. The mean CD4- cell 
count difference was 99 cells/ml of blood with the minimum being -88 and maximum 
552 cells/ml. The standard deviation found was 124 cells/ml. Using the paired T-test, the 
T- Value (DF) was 5.78 (51) and the difference was significant (p <0.0001).  
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Figure 2: Mean CD4 at Baseline and 6-Months for the 52 patients (follow-up at 6 
months) 
 
 
 
Table 12:  CD4-cell count at six months (n=52) 
CD4 cell counts n=52 % 
<200 31 59.62 
200-500 19 36.54 
>500 2 3.85 
 
 
Table 13:  Mean Differences in CD4 Counts (6 months- baseline) 
Variable 
Summary Statistics of CD4 Differences  
(6-months- baseline)  
Paired T-test
N Mean Std Dev Min Max t-value (DF) p-value
CD4 Change  
(6 months – baseline) 52 99 124 -88 552 
 
5.78 (51) 
 
<0.0001
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Conclusion 
 
In conclusion, the prevalence of oral lesions decreased with HAART as the 
immunological function improved. HAART without protease  inhibitors is effective in 
reducing orofacial lesions although HPV infections increased as well as mucosal 
hyperpigmentation. Remission of molluscum contagiosum is slower than other lesions 
like oral candidiasis. There was an increase in the absolute values of CD4-cell counts for 
most patients and one showed no change while 8 had a negative increase.  
 
 
 
 
                                                                    50 
Oral lesions in HIV/AIDS patients before and after HAART treatment.  
 
CHAPTER FIVE: Discussion 
 
In this chapter, the findings of this study are highlighted. It begins by discussing the 
limitations of the study, demographic information of the participants, the effect of 
HAART on the prevalence of oro-facial lesions. 
 
There was a very high loss of participants to follow-up and this was mainly due to the 
political and economic turmoil that prevailed in the country during the run up to the 
elections. The worsening socio-economic conditions resulted in many patients relocating 
and moving out of the cities and into the rural areas and villages. The violent political 
front caused much displacement as people fled, especially after the March 2008 elections 
towards the June election re-run. 
 
Poor communication systems also affected the study: most of the patients did not have 
telephones at home. The postal services were functioning intermittently. Written 
reminders were delivered to the participants’ addresses through the Department of Health 
Education and Promotion within the City of Harare, but follow-up remained low. 
 
The study could not include assessments of viral loads at all stages and CD4-cell counts 
at 3 months due to financial constraints. 
 
The recruitment of children was minimal as most of the children were undernourished, 
very sick and required hospitalization before commencement on HAART. Furthermore, 
the shortage of paediatricians in the department limited HAART initiation in children. 
In summary, lack of funding, the violent political environment, economic and 
communication constraints made it difficult to consolidate the project and to follow it 
through as was originally planned. Extension of the period of follow up was not practical 
due the rising costs and inability to make contact with participants after the six month 
period had passed. This has affected the power of the study and weakened the results 
somewhat, but the findings are still comparable with studies from different continents. 
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Demography 
 
The study was conducted at hospitals that were mandated by the central government of 
Zimbabwe to provide HAART. The selection of patients for HAART is uniform 
throughout the country. As such the findings of the present study especially at baseline, 
are likely to be represent the national picture, where the participants were consecutively 
selected into the study and none of the patients approached refused to participate.  
 
The national prevalence of HIV infection in Zimbabwe is 15.6% with the ratio between 
men and women being 1:1.5 (MOHCW, 2007). In the present study the ratio is 1:1.8 
respectively. These proportions differ from the previous studies conducted in the country 
by Chidzonga, 2003 (1:1) and Jonsson et al, 1998 (4:1). The most likely reason being the 
selection criteria used. It does reflect the shift from higher prevalence in men to women 
over time.  
 
In the present study the most affected age range was in the 31-40 year age group. These 
results concurred with the studies by Chidzonga (2003) and Jonsson et al. (1998). The 
most common mode of HIV transmission was heterosexual. Vertical transmission 
affected tow per cent of children. 
 
Oro-facial lesions 
 
The literature has attested to the fact that HAART is associated with a reduction in oral 
lesions associated with HIV infection (Gaitan Cepeda, 2008; Ramirez-Amador et al, 
2003; Tappuni and Flaming, 2001; Patton et al. 2000; Schmidt-Westhausen et al.2000). 
In developed countries the decline in the prevalence ranged from 10-50% (Hodgson et al. 
2006). In the present study a decrease in prevalence orofacial lesions was reported from 
baseline, through to 3 months and 6 months, despite the fact that patients were lost to 
follow up at all stages.  
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This finding is consistent with other studies:  Schmidt-Westhausen et al (2000) reported a 
reduction from 85.4% before HAART to 8.2% after HAART initiation. The prevalence 
of oral lesions declined from 47.6% to 37.5% after introduction of HAART (Patton et al. 
2000). A study by Ramirez-Amador et al (2003) over a 12 year period reported a 
statistically significant decrease in the prevalence of oral lesions. Tappuni and Fleming 
(2001) reported a prevalence of 30% in patients on any ART and 46% in patients not on 
ART. A reduced prevalence of 30% was found by Ceballos-Salobrena and co-researchers 
in 2000. Tappuni and Flaming (2001) reported a reduction 24%, while Gaitan Cepeda 
(2008) a decline from 66.3% to 46.5% before and after HAART respectively. 
 
Fungal infection has been reported as the most prevalent oral opportunistic infection in 
HIV-seropositive individuals. 70-90% of HIV-infected develop oral candidiasis and 
hence it being considered as a marker for the progression into AIDS (Scully, 2004; 
Vasiliu et al, 2006). Oral candidiasis including median rhomboid glossitis declined from 
73% at baseline to 23% at 3 months to 6% at six months. Similar results were obtained by 
Schmidt-Westhausen et al (2000) and Nicholatau-Galitis et al (2004).  
 
Hamza et al (2006) found a significantly lower risk of oral candidiasis (OR = 0.28; 95% 
CI = 0.18 – 0.44; p = 0.003) in adult patients in Tanzania who were on HAART. These 
researchers reported even better results for patients who had been on HAART for more 
than 6 months. Umadevi et al (2007) in Southern India reported a reduction in oral 
candidiasis in nearly all participants taking HAART. Tappuni and Fleming (2001) 
reported a reduction in the prevalence of oral candidiasis as follows: monotherapy (25%), 
dual therapy (22%) and HAART (17%). HAART including Protease Inhibitors (PIs) has 
a superior effect on oral candidiasis compared to generic HAART due to the direct 
inhibition of asparitic proteinase produced by candida by PIs (Umadevi et al, 2007; 
Nicolatau-Galitis et al, 2004; Arribas et al, 2000). The improvement in immunity as a 
result of an increase in CD4-cell counts due to the effect of any HAART is responsible 
for the reduction in opportunistic infections including oral candidiasis (Umadevi et al, 
Aquino-Garcia et al, Hamza et al, Tappuni and Fleming, 2001). Hodgson et al (2006) 
noted a significant decrease in oral candidiasis from prospective studies analyzed.  
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Hairy leukoplakia has been documented as the second commonest oral opportunistic 
infection after oral candidiasis before HAART therapy is initiated (Ceballos-Salobrena et 
al, 2000; Schmidt-Westhausen et al, 2000; Eyeson et al, 2002; Ramirez-Amador et al, 
2003; Gaitan Cepeda et al, 2008), ranging from 0.42 to 38% (Frezzini et al. 2005). 
Arendorf and Holmes (2000) reported an average prevalence of 6% in Africa. The 
present study reflects the same finding unlike the previous Zimbabwean studies 
(Chidzonga, 2003; Jonsson et al.1998). The prevalence of hairy leukoplakia in the present 
study at baseline was 20%, at 3 months 10% and 6% at 6 months. The difference could 
be due to the immunological status of the patients. The present study had patients with 
severe immunosuppression with CD4- cell counts of =/< 200. 
 
HAART has been reported to decrease the prevalence of oral hairy leukoplakia (Reznik 
and O’Daniels, 2006; Patton et al. 2000; Ramirez-Amador et al. 2003). Greenspan and 
colleagues (2001) registered a reduction of hairy leukoplakia for patients on ART and 
HAART compared to those who were receiving no treatment (p< 0.001). Hamza et al 
(2006) found that patients on HAART had a low risk of hairy leukoplakia. There are 
however, other studies that report no significant changes in prevalence (Miziara and 
Weber (2006); Gaitan Cepeda (2008); Greenspan et al. 2004).  The reduction in the 
prevalence of oral hairy leukoplakia is associated with the increase in CD4- cell count 
(Eyeson et al, 2002). 
 
Hairy leukoplakia is associated with smoking - Sroussi et al (2007) reported the 
prevalence for non-smokers as four times less than smokers. Similar findings were noted 
by Schmidt-Westhausen et al (2000) and Greenspan et al (2004) among women heroin/ 
methadone, cigarettes and/or marijuana users. Frezzini et al (2005) and Flint et al (2006) 
reported a male dominance especially in with men who have sex with men. Hairy 
leukoplakia is a persistent condition that has been reported by most studies including 
after initiation of HAART (Eyeson et al, 2002; Hamza et al, 2006; Gaitan Cepeda, 2008). 
The presence or absence of the lesion therefore reduces its potential to be considered both 
as a sign of HAART failure and a component of IRIS (Flint et al, 2006; Gaitan Cepeda, 
2008). 
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The malignancies strongly associated with HIV infection include Kaposi’s sarcoma. In 
the present study the prevalence dropped from 2% (5/210) to 1% (1/96) and 0% at 6 
months among 52 patients. A steady decline in prevalence has been reported by Jonsson 
et al (1998) and Chidzonga (2003). Frezzini et al (2005) reported the prevalence of oral 
Kaposi’s sarcoma ranging from 0-12% in Africa and 0-38% in North America and 
Europe. The prevalence reported in the present study is in line with those reported in 
other African countries. Another southern African study by Hamza et al (2006) reported a 
prevalence of 3.2% among patients who had received HAART for a period ranging 
between 1-14 months. The risk of Kaposi’s sarcoma was significantly lower for 
individuals who were on HAART in comparison with non-HAART patients after 
controlling CD4-cell count. 
 
Gaitan Cepeda (2008); Greenspan et al (2001); Schmidt-Westhausen et al (2000); 
Ceballos-Salobrena et al (2000) and Corti et al (2007) all reported a significant reduction 
in the prevalence of Kaposi’s sarcoma. While Ramirez-Amador (2003) and Patton and 
colleagues (2000) reported a non-significant decline. The improvement in the immune 
status recognized by the increase in CD4-cell counts and decreased viral load are 
responsible for the decline in Kaposi’s sarcoma among individuals on HAART. The PIs 
have been found to have a direct anti-tumour activity (Frezzini et al, 2005). Apart from 
these findings, Arendorf and Holmes (2000) highlighted the prevalence of Kaposi’s 
sarcoma in relation to the sexual preferences in developed countries, with men who have 
sex with men affected the most. In summary, HAART reduces the prevalence of Kaposi’s 
sarcoma as seem in the present study and reported on other continents. 
 
In the present study, there was no case of Non-Hodgkin’s lymphoma and this could be 
due to the small sample size. It is the second common cancer after Kaposi’s sarcoma and 
the most frequent in children (EC Clearinghouse Classification, 1993). Chidzonga (2003) 
reported a prevalence of 7.1%. Corti et al (2007) noted that the lesion resolved after 
chemotherapy and HAART. They suggested that non-Hodgkin’s lymphoma be 
considered for inclusion in conditions in immune reconstitution syndrome (IRIS).  
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HIV- associated periodontal diseases are among conditions strongly associated with HIV 
infection. In the present study, the prevalence decreased from 7% to 4% and 0% after 6 
months. The prevalence reported from several studies range from 0%-50% (Vaseliu et al, 
2006; Frezzini et al, 2005). Jonsson et al (1998) and Chidzonga (2003) reported a 2% 
prevalence of NUG and 8.3% of NUG/NUP in Zimbabwe before HAART respectively. 
Arendorf and Holmes (2000) noted a higher incidence rate of periodontal diseases in the 
developing world than in the industrialized world. 
 
The recipients of HAART have shown a reduction in the frequency of periodontal 
diseases (Kroidl et al. 2005; Ceballos-Salobrena et al.2000; Patton et al. 2000; Schmidt-
Westhausen et al. 2000; Tappuni and Fleming, 2001; Eyeson et al. 2002). Ramirez-
Amador et al (2003) in their 12-year study noted a significant decline in periodontal 
diseases from baseline. Aquino-Garcia et al (2008) noted reduced frequencies for patients 
on HAART with efavirenz (10.5%) compared to those on HAART with protease 
inhibitors (14.2%). Hamza et al (2006) reported a lower prevalence of NUG among 
HAART and non- HAART patients. An insignificant association between conventional 
gingivitis and low CD4 percent was found by Okunseri et al (2003) among children. 
 
Oral ulcerations had a prevalence of 13% at baseline, at 3 months 9% and six months 6%. 
They included herpes ulcerations, recurrent aphthous ulcers and atypical ulcers.  Frezzini 
and colleagues (2005) reported prevalence of ulcerations ranging from 1.7%-24% while 
Vasiliu et al in 2006 noted 10-30% in both adults and children. Patton et al (2000) 
reported no significant change in oral ulcerations before and after HAART. Nicolatau-
Galitis et al (2004) reported 2.7%, 2.27% and 0% prevalence on patient on no ART, PI-
HAART and double ART respectively. A decline was also reported by Schmidt-
Westhausen et al (2000); Ceballos-Salobrena et al (2000) and Hamza et al (2006). 
 
In the current study the prevalence of herpes simplex virus 1 (HSV-1) remained constant 
at 6% at baseline to 6 months. This could reflect a non-response of the HSV-1 to HAART 
and is mot a good indicator of immune status in HIV patients relative to HIV 
seronegative individuals (Frezzini et al, 2005).  
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The present study reported healed lesions in 16% at baseline and if active lesions were 
included, the prevalence rose to 22%. Miller and colleagues (2006) reported that the 
prevalence of HSV-1 in saliva of HIV positive individuals on HAART was 8 times more 
than in HIV negative people. The HSV-1 prevalence was reportedly higher in patients 
with CD4-cell count of < 200/ml but was not associated with the presence of oral lesions.  
 
Recurrent aphthous ulcerations were reported 3% after 3 months and 0% at six months. 
Eyeson et al (2002) reported a slight increase in prevalence of the condition among 
patients on HAART. Patton et al (2000) reported lower prevalence differences from 
baseline to after HAART use. Chidzonga (2003) reported 10.9% oral ulcers, 5.1 recurrent 
and 5.8% non recurrent ulcerations. Vaseliu et al (2006) reported a prevalence range of 1-
7% for recurrent ulcers. These lesions are very painful and effect oral function, speech, 
mastication and swallowing.  
 
Naidoo and Chikte (2001) reported the prevalence of parotid gland swelling in children 
ranging between 10-30%, and Frezzini et al (2005) reported a prevalence of 3-10% 
among adults. A six per cent prevalence of salivary gland diseases was found in the 
present study with the highest frequency being parotid gland enlargement 4%, 2% and 
10% at baseline, 3 months and 6 months respectively. This is a similar finding to that of 
Patton et al (2000) and Greenspan et al (2001) who also reported an increase following 
HAART. Nicolatou-Galitis et al (2004) reported a rising frequency from 5.4% to 14.3% 
before the era of ART and a drop again to 6.8% after HAART.  
Parotid gland swellings were reported by Okunseri et al (2003) among HIV infected 
children and by Ceballos-Salobrena et al (2000). Parotid gland enlargement is considered 
as a disorder of the CD8-cell (DILS) diffuse infiltrative lymphocytosis syndrome 
(Greenspan et al, 2001, Frezzini et al, 2005).  Hamza et al (2006) reported the highest 
prevalence of parotid gland enlargement of 19.6% in children with no differences among 
HAART patient and non-HAART patients. Flint et al (2006) has suggested that salivary 
gland disease should be included as one of the conditions seen in IRIS as opposed to 
HAART failure.  
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Xerostomia was clinically diagnosed by the dryness of the buccal mucosa and only two 
patients were affected at baseline and none thereafter. The prevalence of xerostomia of 2-
30% was reported by Frezzini at al (2005) and Ceballos-Salobrena et al in (2000). Even 
though the clinical presentation was very low, more than half of the present sample 
reported having experienced dryness of the mouth often or sometimes during the course 
of their HIV disease.  
 
Eyeson et al (2002) reported a statistically higher prevalence of xerostomia in patients on 
HAART compared to those on no HAART. Aquino-Garcia et al (2008) reported 18.4% 
and 17.1% prevalence of xerostomia in efavirenz-HAART and PI-HAART respectively. 
Other studies suggest that Xerostomia is associated with some HAART drugs, however, a 
differential diagnosis regarding the cause of the oral dryness should be made - as 
nucleoside reverse transcriptase inhibitors or protease inhibitors; antidepressants; salivary 
gland tumours and Sjogren syndrome in women have been previously implicated 
(Frezzini et al, 2005; Flint et al, 2006; Hodgson et al,2006). Hodgson et al (2006) found 
an association with women for xerostomia and reduced function of the salivary glands.  
 
Mucosal hyperpigmentation has been reported in a number of studies with prevalence of 
1.8%-10.3% (Ceballos-Salobrena et al, 2000). Hamza et al (2006) documented the 
condition as the second commonest lesion in their study with 20% of their sample taking 
a combination with zidovudine. A high prevalence was reported by Umadevi et al (2007).  
They noted a significant difference in the prevalence associated with CD4 cell counts. In 
participants with >200 CD4-cell counts, high mucosal pigmentation was reported. In the 
present study pigmentation was 6%, 17% and 12% at baseline, 3 months and 6 months 
respectively.    
 
The causes of mucosal hyperpigmentation are mainly associated with the administration 
of zidovudine (Ceballos-Salobrena et al, 2000; Frezzini et al, 2005; Flint et al, 2006, 
Hodgson et al, 2006; Hamza et al, 2006; Umadevi et al, 2007). The mechanism has been 
associated with deregulation of cytokines in HIV infected persons promoting an 
increased release of alpha melanocyte-stimulating hormone; antiretrovirals- zidovudine, 
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antifungals – ketoconazole and Addison disease (Hamza et al, 2006; Umadevi et al 
(2007). In the present study however, no participant was on a combination with 
zidovudine at baseline and only 1 patient at 3 months. At 6 months, 15% got their first 
prescriptions that included zidovudine. The condition should be further investigated. 
 
Other intraoral conditions reported in this study include oral warts (1%) at baseline, 
fissured depapilated tongue (4%), hairy black tongue (2%), and tonsillitis –pharyngitis 
(2%). These conditions were not reported in the later reviews. Oral warts caused by 
human papilloma virus were reported previously as showing a steady increase with the 
use of HAART with protease inhibitors. Schmidt-Westhausen et al (2000) and Patton et 
al (2000) reported a rise in oral warts though this finding was non-significant.  In patients 
on PI-HAART the association of increased warts was found to be highly significant 
(Greenspan et al, 2001). Eyeson et al (2002) reported only 1% with papillomas in patients 
on HAART. Frezzini et al (2005) reported a prevalence of 9.2-18.6% and noted the 
presence of HPV in saliva of 25.3% HIV- positive individuals with 7.6% in HIV- 
negative. Prominence in male gender and a very high presence in individuals who 
practice oro-genital contact were noted (Frezzini et al, 2005; Hodgson et al, 2006 
Umadevi et al, 2007). An association with CD4-cell count has also been reported 
(Frezzini and colleagues, 2005). 
 
The increase in oral warts in patients on PI-HAART has been associated with the 
decrease in viral load although the mechanism is unclear (Frezzini et al, 2005; Hodgson 
et al, 2006). It is also associated with the immune reconstitution syndrome which is 
believed to be linked to the production of immature CD4-cells with compromised 
immunocompetence (Schmidt-Westhausen et al, 2000; Frezzini et al, 2005; Hodgson et 
al, 2006). Regional researchers did not mention any oral warts presence (Jonsson et al, 
1998; Chidzonga, 2003; Hamza at al, 2006). The low prevalence of papillomas in the 
present study is in agreement with other studies which reported no difference in patients 
on non PI-HAART and on HAART (Frezzini et al, 2005). The short period on HAART, 
the type of HAART and the high loss of patients to follow up as well as the heterosexual 
sample could be responsible for the low prevalence in this study.  
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The presence of oral warts has been noted as a risk factor for the development of oral 
malignancies including squamous cell carcinoma (Frezzini et al, 2005; Hodgson et al, 
2006; Flint et al, 2006).  
 
Extraoral lesions reported in the present study include herpes zoster, Molluscum 
contagiosum, planar warts, facial palsy, lymphadenopathy and ringworms/facial rash.  
Hamza et al (2006) reported a prevalence of 0.4% herpes varricella zoster infection and 
25.9% history of herpes zoster infection. In present study, the history of infection was 
higher at 35%. Jonsson et al (1998) and Chidzonga (2003) reported a prevalence of 12% 
and 10.3% respectively. The trigeminal branch is affected in about 17% of herpes zoster 
individuals (Frezzini et al, 2005).  
 
In Zimbabwe the history of the infection is considered important in the selection of 
candidates for HAART. The condition seems to be more prevalent in Africa and appear 
in the same frequencies in HIV- infected and HIV- seronegative individuals (Frezzini et 
al, 2005). There is some controversy as to the association of the condition and low CD4 –
cell count (Frezzini et al, 2005).  
 
The prevalence of cervical lymphadenopathy is rarely reported. In the present study a 
high prevalence of 40% was found while Jonsson et al (1998) and Chidzonga (2003) 
reported 21% and 7.1% respectively.  
Okunseri et al (2003) and Miziara et al (2005) reported a 1.0% and 15.3% in children on 
any HAART. These differences could be in the diagnostic methods used. In Zimbabwe, 
lymphadenopathy prevalence is relatively high and could be used as an indication for 
HIV-infection. The effect of HAART could not be ascertained since 3 and 6 months as 
the condition was not reviewed. 
  
Molluscum contagiosum prevalence in the present study was 9%, 7% and 6% at six 
months. The viral infection is transmitted through skin contact and can be found in both 
HIV–positive and negative individuals. The lesions are more severe in individuals with 
AIDS and CD4-count of <200.  
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A CD4-cell count of less than 50 is accompanied by extensive lesions and large firm 
fleshy doom-shaped swellings usually on the face and neck. In the present study multiple 
non-giant lesions were found 
 
The use of HAART accompanied by an increase in CD4-cell count, leads to the decrease 
in the lesions (Naidoo, 2001; Kekitinwa and Schwarzwald, 2006). Schmidt-Westhausen 
et al (2000) reported a decline in the prevalence of the lesions after initiation of HAART. 
In the present study a reduction in the prevalence was reported consistent with previous 
studies.  
 
Planar warts showed a noticeably high, increasing higher prevalence from 3% at baseline; 
22% at 3 months and 19% at 6 months. This is a lesion that is associated with HPV 
infection which has also been reported to increase in patients on HAART treatment. 
There was also a steady increase in ringworm/facial rash (7% to 10%). This could be 
linked to the use of nevirapine after HAART initiation and use of cotrimoxazole 
prophylaxis prior to HAART. However, in line with other studies reported worldwide, 
the present study also showed a significant decline in the most common oral lesions (oral 
candidiasis, hairy leukoplakia, periodontal lesions, Kaposi’s sarcoma and oral 
ulcerations) after the initiation of HAART. A high prevalence of mucosal 
hyperpigmentation was found, but no association with HAART could be established. 
There was an increase in salivary gland enlargement facial planar warts. 
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CHAPTER SIX: Conclusions and recommendations 
 
The present study detremined the prevalence of orofacial lesions with special reference to 
oral manifestations of HIV in individuals on HAART.  
 
• HAART appears to be effective in reducing the prevalence of oral lesions in persons 
with AIDS likely due to the immunological reconstitution syndrome. 
• Oral candidiasis remains the most prevalent oral opportunistic infection in 
immunosuppresed individuals and hence its important predictive value for 
immunosuppresion defined as CD4-cell count level <200/mL of blood. 
• All oral lesions strongly associated with HIV infection with the exception of non-
Hodgkin’s lymphoma were diagnosed at baseline. 
• CD4 cell count level increased after initiation of HAART. 
• T-lymphocytes that are formed after the introduction of HAART may not provide 
sufficient protection against some lesions like parotid gland disease, HPV conditions 
(planar warts) and the persistence of oral candidiasis at 3 and 6 months. 
• HAART failure was detected in some patients who had negative CD4-cell count at 6 
months compared to the baseline parameters with poor compliance ruled out. 
• At baseline, patients reported experiencing oral pain during the course of their 
disease, eating, drinking and swallowing. 
• Toothache was the most common symptom among HIV patients leading to disturbed 
sleep. 
 
Further longitudinal studies are required in order to ascertain the prevalence of these 
lesions at three and six months and the effect of HAART.  
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Recommendations 
 
The following recommendations should be applied to countries with poor resource 
settings like Zimbabwe. Oral lesions provide an uncomplicated way of identifying 
potentially HIV- infected individuals.  
 
Improvement in identification of oral lesions 
 
• Inclusion of oral health workers in the management team of Opportunistic Infection 
Clinics. The prevalence of oral lesions is high in HIV-infected individuals and the 
effects of the lesions disturb the quality of life of PLWHA. A holistic approach to 
management of HIV–seropositive individuals requires dental surgeons to be 
incorporated in treating the affected.  
• Primary health care workers need to be trained in the diagnosis of oral lesions due to 
their potential in detecting early HIV infection and progression of the disease and 
lately identification of HAART failure and as signs of immune reconstitution 
syndrome (IRIS). 
 
Scaling - up of HAART 
 
• HAART prolongs life: HAART does not only improve the oral health of infected 
individuals but it prolongs life. Zimbabwe is in the epicentre of the AIDS pandemic 
and has a large burden of orphans. Early provision of HAART will save lives and 
reduce the problem of orphans. 
• Improvement in production and social life: AIDS affects the working class and 
experienced workers as the most infected are between 21-60 years of age. 
Debilitating effect of AIDS leads to reduced production capacity of companies and 
eventual loss to death of workers.  
• Reduction in health costs: The cost of treating recurrent opportunistic infections in 
infected individuals is reduced when patients are put on HAART as their immunity 
improves. 
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Increase in oral health research  
 
• HIV and AIDS is a public health problem in sub-Saharan Africa. Improvement in 
the financing of oral health research will assist in the improvement of general health 
of the populations. 
• This study had very few children and the loss of patients to follow-up requires that 
similar studies be conducted so as to improve the inference of the results at 3 and 6 
months to the ordinary populace. 
 
Gender considerations 
 
• The ratio of men to women was almost 1:2. There is need to promote the use of 
preventive methods in women like use of female condoms and economic 
empowerment as poverty make women more vulnerable to HIV infection. 
 
Promotion of oral health associated with HIV and AIDS awareness campaigns 
 
• Oral examination is simple and non-invasive. Self inspection of the mouth should be 
made aware to the general population in the identification of oral lesions associated 
with HIV infection for example angular cheilitis, thrush, hairy leukoplakia, recurrent 
ulcers, Kaposi’s sarcoma and oral warts. 
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APPENDIX I: INFORMED CONSENT FORM 
 
 
UNIVERSITY OF THE WESTERN CAPE 
 
FACULTY OF DENTISTRY 
 
 
SUBJECT INFORMED CONSENT FOR ORAL EXAMINATION 
 
 
Protocol Title: Oral Lesions in HIV/AIDS Patients Before and After HAART  
    Treatment  
 
Name of Researcher: Antonette Masiiwa (Dr) 
 
Phone: 0912 390 012 
 
Project description 
Examination of patients for mouth and facial problems (orofacial lesions) before they are 
started on Antiretroviral Therapy (ARVs), after 3months and 6months of taking ARVs. 
The same patients will be followed up for 6months. 
 
YOUR RIGHTS 
Before you decide whether or not to volunteer for this study, you must understand 
its purpose, how it can help you, and what is expected of you. This process is called 
informed consent. 
 
Purpose of study: 
To find out if Antiretroviral drugs can prevent or help with mouth problems like thrush, 
oral sores, oral cancers, gum infections and others. The oral problems will be compared 
with the CD4-cell counts (the amount of cells [soldiers] that protect the body from getting 
infections and are destroyed by HIV leading to AIDS). 
 
Procedures involved in the study: 
1.Examination of mouth, neck and face area 
2.Taking of small amount of blood for CD4-cell counts 
3.Taking pictures of mouth from a few individuals when necessary. 
 
Discomforts and Risks: 
Little discomfort during the oral examination without pain 
Some minimal pain during bleeding for CD4-cell count blood 
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Potential benefits: 
1.Free consultation including examination of the whole mouth and advice on treatment 
options available 
2.CD4-cell counts will be paid for by the Principal investigator at 3months and those who 
cannot afford at 6months 
3.Review fees will be paid for by the dentist at baseline, 3months and 6months as a token 
of appreciation 
 
Study withdrawal: 
You may choose not to enter the study or withdraw from the study at any time without 
loss of benefits entitled to you. 
 
Confidentiality of records: 
The principal investigator the dentist will keep the information in a lockable cupboard at 
home. The computer version will be accessed by using a password. 
 
Problems/Questions:  
Please ask any questions about this research or consent now. If you have any questions in 
the future please ask Dr Antonette Masiiwa at Gershon Dental Clinic, Beatrice Road 
infectious Disease Hospital. 
Phone:0912 390 012 
 
AUTHORIZATION: 
I have read this paper about the study or it was read to me. I understood the possible risks 
and benefits of this study. I know being in this study is voluntary. I choose to be in this 
study. I know I can stop being in the study and I will not lose my benefits entitled to me. I 
will get a copy of this consent form. (Including all the pages of the consent form) 
 
 
 
Client Signature       Date 
 
 
Client Name (Printed) 
 
 
Researcher signature       Date 
 
 
Witness Signature       Date 
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APPENDIX II: DATA CAPTURE SHEET 
 HAART Oral Health Data Capture Sheet       
          
Date of examination:     
          
Q1 Project code No.         
          
Q2 Hospital code No.         
          
Q3 Patient hospital code No.        
          
Q4 Referral centre code No.        
          
Q5.1 Date of birth   y y mth d    
             
          
Q5.2 Age   y y mth    
               
          
Q6 Gender code     M F   
            
          
             Q7 
 
 
Medical History (from records)        
          
 Condition   Key        
7.1 Tuberculosis Y N        
7.2 STI………………….. Y N        
7.3 Herpes Zooster Y N        
7.4 Oral Thrush Y N        
7.5 Meningitis-cryptococcal Y N        
7.6 Severe persistent rush Y N        
7.7 10% loss of weight Y N        
7.8 Smoking Y N        
7.9 Other Illness (specify)            
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Q8 Physical exam lymphadenopathy & Salivary Glands       
          
8.1 Lymphadenopathy Y N       
8.2 Parotid gland swelling Y N       
8.3 Xerostomia (Dry mouth) Y N       
8.4 Other swellings, specify Y N       
              
Q9 
Appearance of marginal gingivae (Loe & Silness, 
1963)       
 0=normal gingival         
 
1=mild marginal gingivitis, slight colour change & 
oedema       
 
2=moderate gingival inflammmation, redness & 
glazing       
 
3=A distinct red band along the marginal gingiva from papilla 
to papilla     
 
4=Severe inflammation, marked redness & oedema, with ulceration or 
spontaneous bleeding 
 
 
Q10 Oral Mucosa       
 Lesion Baseline 10A 3 months 10B 6 mths 10C 
   Y N Y N Y N 
10.1 No lesion            
10.2 
Pseudomembraneous 
candidiasis         
 
  
10.3 Erythematous candidiasis            
10.4 Hyperplastic candidiasis            
10.5 Angular cheilitis            
10.6 Hairy leukoplakia            
10.7 Herpetic ulceration            
10.8 Aphthous ulceration            
10.9 Atypical ulceration            
10.1 Kaposi's sarcoma            
10.11 Non-Hodgkin Lymphoma            
10.12 Oral warts            
10.13 Other (specify)            
 HIV STATUS        
11.2 HIV Test       
 Item            
11.3 Date of HIV diagnosis            
11.4 Route of transmission Sexual 
IV 
Drugs Transfusion Version 
 
  
   Baseline   3 months     
11.5 WHO Clinical Stage            
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11.6 CD4 count            
11.7 CD4 count date taken            
        
Q12.1 
Date started on cotrimoxazole 
/ fluconazole yy mth date  
 
 
 Prophylaxis          
        
12.2 
Date stopped on 
cotrimoxazole/ fluconazole yy mth date  
 
 
 Prophylaxis          
        
Q13 
HAART Treatment 
combinations:     
 
 
        
13.1 Date started with HAART:            
   Baseline   3 months     
 Combinations: Y N Y N  N 
 first line regimen            
13.2 
stavudine + lamivudine + 
nevirapine         
 
  
13.3 
stavudine + lamivudine + 
effavirenz         
 
  
13.4 
zidovudine + lamivudine + 
nevirapine         
 
  
13.5 
zidovudine + lamivudine + 
effavirenz         
 
  
 second line regimen            
13.6 
abacavir + kaletra 
(lopinavir/ritonavir) + 
didanosine         
 
  
13.7 
abacavir + saquinavir/ritonavir + 
didanosine         
 
  
13.8 other (specify)       
        
Q14 Treatment for oral lesions:       
  Baseline   3 months    
 Medication Y N Y N  N 
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15. History of Oral Problems 
 
15 Have you ever had any sores/ ulcers in your mouth? Y N 
15.1 If Y, what problem, sores, ulcers did you have? 
 
 
15.2 If Y, when did you have them? 
15.3 If Y, did they cause you pain or discomfort? Y N 
 If Y, please explain for how long 
15.3 Are you having any pain or discomfort with your mouth now?  Y N 
15.4 If Y, is this pain /discomfort causing difficulty with:   
 Eating   
 Drinking   
 Swallowing   
 Speaking   
 Working   
 Sleeping   
 Other (specify)   
 
16. Oral Function 
 
16 Have you had a painful throat? 
Often 
Sometimes Never 
16.1 Have you had problems swallowing liquids? 
Often 
Sometimes Never 
16.2 Have you had problems swallowing solid food? 
Often 
Sometimes Never 
 If Y, when did you have them? 
16.3 Have you had a problem with a dry mouth 
Often 
Sometimes Never 
16.4 Have you had problems with your sense of taste? 
Often 
Sometimes Never 
16.5 Have you had problems with your teeth? Y N 
 If yes, explain 
 
  
16.6 Have you had trouble eating? Y N 
 If yes, explain 
 
  
16.7 Have you had problems with your gums? Y N 
 If yes, please explain 
 
  
16.8 Have any of your mouth problems stopped you from 
sleeping? 
Y N 
 If yes, please explain   
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APPENDIX III: ORAL MUCOSAL EXAMINATION 
 
Topographical classification of oral mucosa 
 
CODE CONDITION CODE LOCATION 
1 No abnormal condition 11 Upper lip 
2 Angular cheilitis 12 Lower lip 
3 Commisural pits 13 Mucosa of upper lip 
4 Traumatic lesions 14 Mucosa of lower lip 
5 Geographic tongue 15 Mucosa around corner of mouth on r side 
6 Dentoalveolar abscess 16 Mucosa around corner of mouth on l side 
7 Herpes labialis 17 Cheek mucosa on r side of patient 
8 Fissured tongue 18 Cheek mucosa on l side of patient 
9 Ulcerations 19 Mucosa of upper jaw, bet lip/cheek & gum 
10 Herpetic gingivostomatitis 20 Mucosa of upper jaw, bet lip/cheek & gum 
11 ANUG 21 Mucosa of gums of upper teeth 
12 Verruca vulgaris 22 Mucosa of gums of lower teeth 
13 Papilloma 23 Top surface of tongue 
14 Focal epithelial hyperplasia 24 Sides of tongue 
15 Melanotic hyperpigmentation 25 Undersurface of tongue 
16 Candidiasis 26 Mucosa bet under surface of tongue & gums 
of lower teeth 
17 Other 27 Mucosa of hard palate 
  28 Mucosa of soft palate 
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Criteria used for diagnosis of oral mucosal lesions 
 
Lesion 
Criteria 
1. White non-adherent lesions 
(a) Candidiasis: acute pseudomembraneous Creamy white patches, wipeable leaving red patches 
(b) Aspirin Burn White necrotic epithelium; Will slough off/rub off to 
reveal ulcer underneath 
  
2. White or white/red adherent lesions 
Local aetiology suspected 
 
(a) Frictional white lesion Whitish or greyish patch on the mucosa which cannot be 
rubbed off 
(b) Cheek & lip biting Oral mucosa shows a rough, grey-white, macerated 
surface with irregular, flaky desquamation. Lesion is 
located self-infliction by chewing is possible. 
Local aetiology not present/known 
 
(a) Leukoplakia - A white patch, or plaque, that cannot be wiped off 
and cannot be characterized clinically or 
pathologically as any other disease 
- Varies from  small circumscribed areas to extensive 
lesions involving a large area of the mucosa 
- Surface appearance is variable; 
- May be smooth or wrinkled 
- Smooth-surfaced but traversed by small cracks    
- Nodular or speckled  
- Colour can be white, whitish-yellow or grey 
Recommended subdivisions: 
- homogeneous: lesions that are uniformly white with 
smooth or corrugated surface 
- non-homogeneous: lesions in which part is white 
and part appears reddened.  Three types have been 
described: 
- Erythroleukoplakia (erosive leukoplakia) – white 
lesion that includes red areas 
- Nodular leukoplakia – lesion with slightly raised 
white areas (granules or nodules) 
- Verrucous leukoplakia – exophytic lesion with 
irregular sharps or blunt projections. 
(b) Candidiasis, chronic hyperplastic - Adherent white plaque, may be flat or elevated 
- May incorporate erythematous areas 
(c) Red lesions  
Candidiasis, acute atrophic 
 
 
Erythroplakia 
- Bright red atrophic patches on mucosa 
- burning or itching sensation is common, palate is a 
common location; bright red patches or plaques of 
mucosa that cannot be characterized clinically or 
pathologically as any other condition 
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Lesion 
Criteria 
3. Perioral conditions 
(a) Actinic keratosis 
(actinic elastosis or actinic cheilitis) 
 
- Vermillion border poorly defined (loss of distinction 
between vermillion border, labial mucosa and skin 
- Border may have localized crust formation and/or a 
whitish colour, common in patients with outdoor 
occupations 
    (b) Angular cheilitis - Bilateral folds in the skin of the labial commissures, 
surface tissue appears wrinkled, fissured or cracked 
- No tendency to bleeding, although a crusted exudate 
may be present 
- Mucosal surface of commissures are usually not 
involved 
4. Tongue lesions 
(a) Fissured tongue 
 
- Shallow or deep fissures on the dorsum of the 
tongue; most common pattern is a marked central 
fissure, from which smaller fissures radiate laterally  
- Food debris may accumulate in fissures and result in 
inflammation 
- Often association with geographic tongue 
  (b) Geographic tongue - Localized absence of filiform papillae 
- Affected areas are irregularly shaped 
- Areas change location over time 
  (c) Hairy tongue - Overgrowth of filiform papillae in which they 
become elongated or thickened 
- Colour of tongue varies from white to yellow or 
greenish, but is most commonly brown or black 
  (d)  Median rhomboid glossitis - Deep red or white ovoid area devoid of tongue 
papillae 
- Located in the central dorsum of the tongue near the 
foramen caecum 
- Sometimes demarcated from surrounding mucosa by 
a furrow 
  (e) Hairy leukoplakia - Flat white lesion which cannot be rubbed off 
- Corrugated surface appearance 
- Usually found on the lateral borders of the tongue  
5.    Ulcers 
(a) ANUG 
 
 
“Punched-out” papillae 
- Pseudomembranous exudate 
- Bleeding upon slight palpation 
- Pain, distinctive oral odour 
 (b) Herpetic gingivostomatitis (primary herpes) - Severe gingival inflammation 
- Whitish, serofibrinous exudate 
- Vesicles and/or shallow ulcers; pain, malaise, fever 
(c) Herpes labialis (secondary herpes) - Clusters of vesicles or crusts 
- Found on vermillion border 
- Duration: less than three weeks 
- History of recurrence 
(d) Recurrent aphthous ulceration - Well-defined, greyish-white ulcer(s) 
- Ulcers surrounded by red halo 
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- Pain; duration: 10-21 days; history of recurrence 
Lesion 
Criteria 
(e)  Ulcer (non-specific) - Traumatic ulcers 
- Idiopathic ulcers 
- Toothbrushing-induced ulcers 
6.  Elevated lesions 
(a) Gingival hyperplasia 
 
- Enlarged gingiva and interdental papillae 
- Papillae may be stippled or glazed in appearance 
- Usually presents as a generalized condition 
(b) Mucocele - Well-defined, fluid-filled swelling 
- Normal pink or bluish colour 
- Commonly found on labial mucosa and floor of the 
mouth (ranula) 
(c) Focal epithelial hyperplasia 
(Hick’s disease) 
- Multiple circumscribed soft elevations 
- Whitish to normal coloration 
- Primary seen in American Indians and Eskimos 
(d) Papilloma - Exophytic growth, usually pedunculated 
- Verrucous, “cauliflower-like’ surface 
- White or greyish colour is characteristic 
(e) Verruca vulgaris - Sessile or pedunculated lesion(s) 
- Papillomatous surface; common locations are the 
labial commissure & gingiva 
(f) Tumour (non-specific) 
 
 
Kaposi’s sarcoma 
- Oral tumour(s) presenting with bluish or reddish 
macules in early stages 
- Lesions later become darker, elevated and 
sometimes lobular 
- The palate and gingiva are the common intraoral 
locations 
Pigmented lesions 
(a) Amalgam tattoo 
- Asymptomatic pigmented area, non-elevated 
- Bluish, blackish or slate-grey colour 
- Borders are usually poorly defined 
- Mucosal surface appears normal 
(b) Naevus - Well-circumscribed flat or elevated area 
- Pigmented with melanin 
- Colour range from blue to brown or black 
- Cannot be classified as due to exogenous 
pigmentation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
